argenx SE (ARGX)

NASDAQ: ARGX · IEX Real-Time Price · USD
393.72
-4.87 (-1.22%)
Mar 28, 2024, 4:00 PM EDT - Market closed
-1.22%
Market Cap 23.35B
Revenue (ttm) 39.48M
Net Income (ttm) -327.84M
Shares Out 59.30M
EPS (ttm) -5.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,199
Open 397.61
Previous Close 398.59
Day's Range 391.70 - 397.79
52-Week Range 327.73 - 550.76
Beta 0.35
Analysts Strong Buy
Price Target 522.06 (+32.6%)
Earnings Date Mar 2, 2023

About ARGX

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2017
Employees 1,148
Stock Exchange NASDAQ
Ticker Symbol ARGX
Full Company Profile

Financial Performance

In 2023, argenx SE's revenue was 35.53 million, an increase of 254.41% compared to the previous year's 10.03 million. Losses were -295.05 million, -58.42% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $522.06, which is an increase of 32.60% from the latest price.

Price Target
$522.06
(32.60% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amster...

2 days ago - GlobeNewsWire

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

2 days ago - GlobeNewsWire

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)

3 days ago - GlobeNewsWire

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term...

21 days ago - GlobeNewsWire

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2...

4 weeks ago - GlobeNewsWire

argenx to Present at Upcoming Investor Conferences

February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

4 weeks ago - GlobeNewsWire

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

5 weeks ago - GlobeNewsWire

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART ® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM...

5 weeks ago - GlobeNewsWire

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

Availability of VYVGART ® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the N...

2 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...

2 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...

2 months ago - Accesswire

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...

2 months ago - Accesswire

argenx Highlights 2024 Strategic Priorities

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART ® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-...

2 months ago - GlobeNewsWire

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Ti...

3 months ago - GlobeNewsWire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...

3 months ago - Accesswire

ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...

3 months ago - Accesswire

This biotech stock is down 25% on Wednesday: find out why

Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.

3 months ago - Invezz

Argenx stock dives by a third after late-stage trial didn't meet goals

Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigi...

3 months ago - Market Watch

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, ...

3 months ago - GlobeNewsWire

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Regulated information – Inside information

4 months ago - GlobeNewsWire

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enab...

4 months ago - GlobeNewsWire

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia...

5 months ago - GlobeNewsWire

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

$329 million in third quarter global net product sales On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host c...

5 months ago - GlobeNewsWire

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

5 months ago - GlobeNewsWire

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

Amsterdam, The Netherlands — Sep. 2 1 , 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...

6 months ago - GlobeNewsWire